# US 2017/0283877 A1 · Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2017/0283877 A1 - Document ID: US20170283877A1 - Status: Published application - Kind: A1 - Application number: 15/276,131 - Filed: 2016-09-26 - Published: 2017-10-05 - Earliest claimed: 2010-12-20 - Assignees: University of Notre Dame - Applicants: University of Notre Dame - Inventors: Steven Buechler; Amanda B. Hummon - Web page: https://patentgrep.com/patent/US20170283877A1 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - C12N 5/0693: {Tumour cells; Cancer cells} - C12Q 1/686: Polymerase chain reaction [PCR] - G01N 33/57535: of the large intestine, e.g. colon, rectum or anus - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/118: Prognosis of disease development - C12Q 2600/158: Expression markers - G01N 2800/54: Determining the risk of relapse - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed. ## Claims ### Claim 1 A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of: CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, and MMP28. ### Claim 2 A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of: CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, MMP28, CDKN2B, GADD45A, and CCND1. ### Claim 3 A panel of probes for indicating a 5-year RCC relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of CDX2 and FAM69A. ### Claim 4 (depends on 1, 2, 3) The panel of probes of claim 1, 2 or 3, wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface. ### Claim 5 (depends on 1, 2, 3) The panel of probes of claim 1, 2 or 3 wherein the detectable label is a fluorescent label or a radiolabel. ### Claim 6 (depends on 4) The panel of probes of claim 4, wherein the solid surface is nylon, plastic, silicon, or ceramic. ### Claim 7 (depends on 4) The panel of probes of claim 4 wherein the solid surface is a silicon wafer. ### Claim 8 (depends on 4) The panel of probes of claim 4 wherein the solid surface is a glass. ### Claim 9 (depends on 8) The panel of probes of claim 8 wherein the glass is a glass slide or a glass chip. ### Claim 10 (depends on 4) The panel of probes of claim 4 wherein the probes are fixed to the solid surface by a covalent bond. ### Claim 11 A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of: CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, and MMP28. ### Claim 12 (depends on 11) The panel of probes of claim 11, wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface. ### Claim 13 (depends on 11) The panel of probes of claim 11, wherein the detectable label is a fluorescent label or a radiolabel. ### Claim 14 (depends on 12) The panel of probes of claim 12, wherein the solid surface is nylon, plastic, silicon, or ceramic. ### Claim 15 (depends on 12) The panel of probes of claim 12 wherein the solid surface is a silicon wafer. ### Claim 16 (depends on 12) The panel of probes of claim 12 wherein the solid surface is glass. ### Claim 17 (depends on 16) The panel of probes of claim 16 wherein the glass is a glass slide or a glass chip. ### Claim 18 (depends on 12) The panel of probes of claim 12 wherein the probes are fixed to the solid surface by a covalent bond. ### Claim 19 A diagnostic screening tool for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said diagnostic screening tool comprising a panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of: CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, and MMP28. ### Claim 20 (depends on 19) The diagnostic screening tool of claim 19 wherein the detectably labeled single-stranded polynucleotides are immobilized on a solid surface.